Navigation Links
Neurocrine Biosciences Reports First Quarter 2012 Results
Date:5/2/2012

is study assessed once-daily NBI-98854 (12.5mg or 50mg) over a two-week dosing period in 37 randomized subjects. Based on the positive outcome of this study the Company is planning to launch a large Phase IIb trial in mid-2012. This placebo controlled, double-blind, parallel design, multiple dose, twelve week study will assess six-week dosing of NBI-98854, against placebo, followed by six weeks of active treatment with NBI-98854. The study will incorporate a capsule formulation of NBI-98854.

In January of 2012, the Company was notified that the FDA Division of Psychiatry Products had granted Fast Track status to NBI-98854 for neuroleptic-induced tardive dyskinesia. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious diseases and address unmet medical needs.

Urocortin 2 Update
The Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is conducting a Phase II study of urocortin 2 in acute decompensated heart failure patients. This study is now complete and top-line results are expected shortly.

The Company has completed several Phase I studies and two Phase II studies of urocortin 2 in patients with stable congestive heart failure. These Phase II studies showed urocortin 2 to be well tolerated with positive hemodynamic effects as evidenced by increases in cardiac output and efficiency.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 800-894-5910 (US) or 785-424-1052 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com<
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Doctors from the Sheikh Zayed ... National Health System are the first in ... osteoma, a benign but painful bone tumor that commonly ... magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. Two patients, ... Shah , have been treated successfully in a research ...
(Date:5/27/2015)... 2015 The report " Tube Packaging Market ... Oral Care, Food & beverages, Pharmaceuticals, Consumer Goods), by Material ... - Trends & Forecasts to 2020", published by MarketsandMarkets, The ... a CAGR of 6.65% from 2015, to reach $8,638.9 Million ... Tables and   61 F igures spread thro ...
(Date:5/27/2015)... , May 27, 2015  Vital Access Corp. announced ... credit facility with Deerfield Management, a healthcare investment firm. ... Vital Access, continued global expansion of its innovative VWING™ ... the Company,s proprietary vascular access platform. "Vital ... financial partner. Deerfield is a healthcare investor with great ...
Breaking Medicine Technology:Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4Tube Packaging Market Worth $8.63 Billion by 2020 2Tube Packaging Market Worth $8.63 Billion by 2020 3Tube Packaging Market Worth $8.63 Billion by 2020 4Vital Access Receives $10 Million Financing Commitment from Deerfield 2Vital Access Receives $10 Million Financing Commitment from Deerfield 3
(Date:5/27/2015)... Dr. Omar Ibrahimi, Dermatologist and Director ... has been selected as part of a controlled launch ... the only physician in Connecticut) to offer the new ... removal of submental fat (double chin). The procedure is ... surgery and minimal risks. Dr. Ibrahimi is an invited ...
(Date:5/27/2015)... 27, 2015 In support of a ... issue of the Journal of American Geriatrics Society about ... obesity, Bedford Commons OB-GYN P.A . is reiterating ... sweetener-flavored beverages. , To examine the relationship between ... San Antonio Longitudinal Study of Aging (SALSA) tracked the ...
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 – Memorial ... healthcare provider along the Gulf Coast to pioneer ... In partnership with MD Revolution, a digital care ... program that enables healthcare providers to easily meet ... new, user-friendly program is designed to improve patient ...
(Date:5/27/2015)... On June 5, Plan B [the agency ... LifeSource to host Donate Your Break, a public blood ... LifeSource donor coach outside of 116 W. Illinois (at ... for whole blood units is highest for LifeSource, the ... LifeSource requires approximately 1,000 donations per day to maintain ...
(Date:5/27/2015)... Meadows, IL (PRWEB) May 27, 2015 ... release of its SonarMD Platform, a first-of-its ... monitoring and managing patients with chronic gastrointestinal ... Kosinski, MD, MBA, the application allows physicians ... visits through the ongoing use of electronic ...
Breaking Medicine News(10 mins):Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... LAKE CITYFindings of a clinical trial reported at SNM,s ... agent could improve diagnosis of recurrent prostate cancer and ... "Despite definitive treatment, about 30 percent ... of the division of nuclear medicine and molecular imaging ...
... Public Health (HSPH) have found that children and adolescents ... smoke-free public places have significantly lower levels of a ... in counties with no smoke-free laws. The children ... laws had 39% lower prevalence of cotinine in their ...
... results from a major clinical trial show that ... women with advanced ovarian cancer and then continuing ... extends progression-free survival. Women receiving the new treatment ... 14.1 months, compared to 10.3 months for women ...
... June 5 The combination of two different chemotherapies ... cancers is not effective against advanced melanoma, according to ... 46th annual meeting of the American Society of Clinical ... we learn something important about the treatment of melanoma," ...
... and Tasigna than Gleevec , SATURDAY, June 5 (HealthDay ... (Tasigna), appear better than imatinib (Gleevec) in treating patients ... considered as first-line treatments, two new studies show. , ... be presented Saturday at the American Society of Clinical ...
... -- Two drugs approved for treatment of drug-resistant chronic ... a first therapy than the existing front-line medication, according ... England Journal of Medicine . Separate international ... year of treatment between the standard-of-care drug imatinib, also ...
Cached Medicine News:Health News:Molecular imaging detects recurrent prostate cancer 2Health News:Smoke-free air laws effective at protecting children from secondhand smoke 2Health News:New treatment regimen shown effective against advanced ovarian cancer 2Health News:Combination treatment regimen not effective against advanced melanoma 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 3Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 4Health News:Second-line CML drugs evoke faster, better front-line remissions 2Health News:Second-line CML drugs evoke faster, better front-line remissions 3
... The OcuLight family of infrared laser ... SLx models. These diode lasers serve as ... devices and applications, require no regular maintenance ... with their compact design. The OcuLight SLx ...
... mid range space saver specular microscope. It has ... the corneal endothelium automatically. It also has the ... central area. The image of the cells is ... with the system., This model is exactly the ...
... Danker Laboratories manufacturers ... RGP orthokeratology lenses (also ... or "Corneal Reshaping" Lenses) ... specifications and demanding standards ...
... The JSZ Orthokeratology (oprifocon A) ... permeable contact lenses used for ... corrects nearsightedness (myopia). The patient ... removes them in the morning. ...
Medicine Products: